Alumis (ALMS) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Seaport Therapeutics is the larger company by market cap ($961.4 million vs $858.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | SPTX |
|---|---|---|
| Share price | $6.64 | $17.96 |
| Market cap | $858.80M | $961.41M |
| 1-day change | -1.99% | +0.17% |
| YTD return | -30.64% | — |
| 1-year return | +50.11% | — |
| EPS (TTM) | $-3.86 | $-5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $28.38 |
| 52-week low | $4.28 | $14.85 |
| Distance from 52-week high | -78.84% | -36.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +384.25% | +113.20% |
| Average volume | 2.43M | 182.18K |
| Shares outstanding | 129.44M | 53.53M |
| Employees | 237 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ALMS vs SPTX FAQ
Which is bigger, Alumis or Seaport Therapeutics?
Seaport Therapeutics (SPTX) is larger, with a market capitalization of $961.41M compared with $858.80M for Alumis (ALMS).
Are Alumis and Seaport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.